Concepts (328)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastroenterology | 24 | 2006 | 98 | 4.380 |
Why?
|
| Liver Diseases | 17 | 2014 | 193 | 2.860 |
Why?
|
| Liver Failure, Acute | 9 | 2021 | 49 | 2.220 |
Why?
|
| Liver Transplantation | 13 | 2021 | 400 | 2.010 |
Why?
|
| Liver Cirrhosis | 13 | 2017 | 301 | 1.950 |
Why?
|
| History, 20th Century | 34 | 2006 | 248 | 1.870 |
Why?
|
| Chemical and Drug Induced Liver Injury | 6 | 2023 | 131 | 1.730 |
Why?
|
| History, 19th Century | 22 | 2006 | 95 | 1.260 |
Why?
|
| Liver Diseases, Alcoholic | 4 | 2012 | 27 | 1.220 |
Why?
|
| Liver | 12 | 2016 | 1118 | 1.210 |
Why?
|
| Alcohol Drinking | 7 | 2014 | 805 | 1.170 |
Why?
|
| Liver Neoplasms | 6 | 2015 | 334 | 1.120 |
Why?
|
| End Stage Liver Disease | 4 | 2021 | 60 | 1.100 |
Why?
|
| Gastric Antral Vascular Ectasia | 2 | 2018 | 6 | 1.020 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2015 | 163 | 0.970 |
Why?
|
| Glucuronates | 2 | 2012 | 19 | 0.840 |
Why?
|
| History, Ancient | 14 | 2006 | 25 | 0.830 |
Why?
|
| Humans | 79 | 2023 | 68618 | 0.790 |
Why?
|
| Esophageal and Gastric Varices | 4 | 2017 | 47 | 0.770 |
Why?
|
| Hepatocytes | 5 | 2006 | 205 | 0.730 |
Why?
|
| Blood Coagulation Disorders | 2 | 2021 | 45 | 0.610 |
Why?
|
| Decision Support Techniques | 2 | 2017 | 191 | 0.600 |
Why?
|
| Biopsy | 3 | 2011 | 540 | 0.590 |
Why?
|
| Ascites | 4 | 2015 | 38 | 0.570 |
Why?
|
| Glycerophospholipids | 2 | 2014 | 20 | 0.560 |
Why?
|
| History, 17th Century | 9 | 2006 | 17 | 0.540 |
Why?
|
| History, 18th Century | 9 | 2006 | 26 | 0.540 |
Why?
|
| Nontherapeutic Human Experimentation | 2 | 2006 | 3 | 0.540 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2011 | 171 | 0.540 |
Why?
|
| Hemorrhage | 2 | 2021 | 328 | 0.520 |
Why?
|
| Middle Aged | 25 | 2021 | 21147 | 0.510 |
Why?
|
| Famous Persons | 3 | 2003 | 15 | 0.480 |
Why?
|
| Peptides | 3 | 2005 | 455 | 0.450 |
Why?
|
| Collagen Type I | 2 | 2006 | 175 | 0.440 |
Why?
|
| Male | 30 | 2021 | 37321 | 0.440 |
Why?
|
| Models, Theoretical | 1 | 2016 | 384 | 0.430 |
Why?
|
| Music | 2 | 2003 | 7 | 0.430 |
Why?
|
| Liver Cirrhosis, Alcoholic | 3 | 2008 | 14 | 0.420 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 839 | 0.420 |
Why?
|
| Sulfuric Acid Esters | 1 | 2012 | 7 | 0.420 |
Why?
|
| International Normalized Ratio | 1 | 2012 | 23 | 0.420 |
Why?
|
| Prognosis | 10 | 2021 | 2093 | 0.420 |
Why?
|
| Hair | 1 | 2012 | 46 | 0.410 |
Why?
|
| Hepatic Veins | 1 | 2011 | 13 | 0.400 |
Why?
|
| Analgesics | 1 | 2012 | 118 | 0.390 |
Why?
|
| Pulmonary Veins | 1 | 2011 | 56 | 0.380 |
Why?
|
| Chronic Pain | 1 | 2012 | 110 | 0.380 |
Why?
|
| Adult | 20 | 2021 | 21403 | 0.380 |
Why?
|
| Severity of Illness Index | 8 | 2021 | 1851 | 0.380 |
Why?
|
| Female | 26 | 2021 | 38074 | 0.370 |
Why?
|
| Pain Management | 1 | 2012 | 186 | 0.370 |
Why?
|
| Endothelin-1 | 1 | 2011 | 122 | 0.360 |
Why?
|
| Cardiac Catheterization | 1 | 2012 | 419 | 0.340 |
Why?
|
| England | 6 | 2005 | 64 | 0.340 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2009 | 9 | 0.330 |
Why?
|
| Fibroblasts | 2 | 2006 | 902 | 0.330 |
Why?
|
| Acetamides | 2 | 2021 | 17 | 0.320 |
Why?
|
| Symbolism | 2 | 2005 | 3 | 0.300 |
Why?
|
| Herpesvirus 4, Human | 1 | 2007 | 30 | 0.290 |
Why?
|
| Acetaminophen | 3 | 2021 | 111 | 0.290 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2007 | 37 | 0.290 |
Why?
|
| Europe | 5 | 2004 | 196 | 0.280 |
Why?
|
| Porphyrias | 1 | 2006 | 3 | 0.280 |
Why?
|
| Retrospective Studies | 7 | 2018 | 7277 | 0.280 |
Why?
|
| Porphyrins | 1 | 2006 | 15 | 0.280 |
Why?
|
| Proteins | 2 | 2016 | 474 | 0.270 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 2 | 2005 | 37 | 0.270 |
Why?
|
| Hypertension, Pulmonary | 1 | 2009 | 232 | 0.270 |
Why?
|
| Integrin alpha2beta1 | 1 | 2006 | 2 | 0.270 |
Why?
|
| Integrin alpha1beta1 | 1 | 2006 | 5 | 0.270 |
Why?
|
| Sensitivity and Specificity | 5 | 2016 | 1753 | 0.270 |
Why?
|
| Jaundice | 2 | 2004 | 13 | 0.270 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2006 | 65 | 0.260 |
Why?
|
| Bile | 1 | 2005 | 35 | 0.260 |
Why?
|
| Receptors, Cytokine | 1 | 2005 | 19 | 0.260 |
Why?
|
| Growth Inhibitors | 1 | 2005 | 33 | 0.260 |
Why?
|
| Gene Expression | 2 | 2005 | 770 | 0.260 |
Why?
|
| Interferons | 1 | 2005 | 36 | 0.250 |
Why?
|
| Cholangiography | 1 | 2005 | 55 | 0.250 |
Why?
|
| Rodentia | 1 | 2005 | 27 | 0.250 |
Why?
|
| Hepatitis B | 1 | 2005 | 42 | 0.250 |
Why?
|
| United States | 9 | 2017 | 7367 | 0.250 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2004 | 3 | 0.250 |
Why?
|
| Hemochromatosis | 1 | 2004 | 13 | 0.250 |
Why?
|
| Peritonitis | 1 | 2004 | 46 | 0.240 |
Why?
|
| Mythology | 1 | 2004 | 1 | 0.240 |
Why?
|
| Philosophy, Medical | 1 | 2004 | 12 | 0.240 |
Why?
|
| Prospective Studies | 5 | 2016 | 3705 | 0.240 |
Why?
|
| Contraceptives, Oral | 1 | 2004 | 28 | 0.240 |
Why?
|
| Predictive Value of Tests | 6 | 2017 | 1465 | 0.240 |
Why?
|
| Amyloidosis | 1 | 2004 | 48 | 0.230 |
Why?
|
| Physical Examination | 1 | 2005 | 152 | 0.230 |
Why?
|
| Medical Oncology | 1 | 2005 | 110 | 0.230 |
Why?
|
| Pruritus | 1 | 2004 | 35 | 0.230 |
Why?
|
| Risk Factors | 5 | 2017 | 5731 | 0.230 |
Why?
|
| Hepatitis C | 1 | 2005 | 114 | 0.230 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2003 | 7 | 0.230 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2003 | 22 | 0.230 |
Why?
|
| Coloring Agents | 1 | 2004 | 66 | 0.230 |
Why?
|
| Needles | 1 | 2003 | 34 | 0.230 |
Why?
|
| Mushroom Poisoning | 1 | 2003 | 4 | 0.220 |
Why?
|
| Liver Failure | 1 | 2003 | 27 | 0.220 |
Why?
|
| Portoenterostomy, Hepatic | 1 | 2003 | 1 | 0.220 |
Why?
|
| Esophagoscopes | 1 | 2003 | 5 | 0.220 |
Why?
|
| Biliary Atresia | 1 | 2003 | 7 | 0.220 |
Why?
|
| Chemical and Drug Induced Liver Injury, Chronic | 1 | 2023 | 3 | 0.220 |
Why?
|
| Electric Power Supplies | 1 | 2003 | 26 | 0.220 |
Why?
|
| Pathology | 1 | 2003 | 17 | 0.220 |
Why?
|
| Antiviral Agents | 1 | 2005 | 211 | 0.220 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2003 | 9 | 0.220 |
Why?
|
| Adenoma | 1 | 2004 | 132 | 0.220 |
Why?
|
| Anatomy | 1 | 2003 | 36 | 0.220 |
Why?
|
| Publishing | 1 | 2004 | 89 | 0.210 |
Why?
|
| Biomarkers | 4 | 2014 | 1593 | 0.210 |
Why?
|
| Endoscopy, Digestive System | 1 | 2003 | 78 | 0.210 |
Why?
|
| Alcoholic Beverages | 1 | 2002 | 18 | 0.210 |
Why?
|
| Hepatitis, Chronic | 1 | 2002 | 3 | 0.210 |
Why?
|
| Paracentesis | 1 | 2002 | 25 | 0.210 |
Why?
|
| Hyperbilirubinemia | 1 | 2002 | 12 | 0.210 |
Why?
|
| Pathology, Clinical | 1 | 2002 | 16 | 0.210 |
Why?
|
| Phosphoproteins | 2 | 2016 | 202 | 0.200 |
Why?
|
| Nevus | 1 | 2002 | 17 | 0.200 |
Why?
|
| Hepatic Encephalopathy | 1 | 2002 | 25 | 0.200 |
Why?
|
| Cell Culture Techniques | 1 | 2002 | 189 | 0.200 |
Why?
|
| RNA-Binding Proteins | 2 | 2016 | 215 | 0.200 |
Why?
|
| Point-of-Care Testing | 1 | 2021 | 12 | 0.190 |
Why?
|
| Cross-Sectional Studies | 3 | 2012 | 2279 | 0.190 |
Why?
|
| Aged | 10 | 2021 | 14862 | 0.190 |
Why?
|
| Animals | 10 | 2007 | 20881 | 0.180 |
Why?
|
| Metaphor | 3 | 2005 | 5 | 0.180 |
Why?
|
| Cytokines | 1 | 2005 | 866 | 0.180 |
Why?
|
| Oncostatin M | 3 | 2005 | 5 | 0.180 |
Why?
|
| Substance Abuse Detection | 2 | 2012 | 66 | 0.180 |
Why?
|
| History, 16th Century | 3 | 2005 | 8 | 0.180 |
Why?
|
| Breath Tests | 2 | 2021 | 23 | 0.180 |
Why?
|
| Heart Failure | 1 | 2009 | 1180 | 0.180 |
Why?
|
| Adolescent | 7 | 2021 | 8912 | 0.170 |
Why?
|
| RNA, Neoplasm | 2 | 2016 | 76 | 0.160 |
Why?
|
| Mitochondria | 1 | 2003 | 643 | 0.150 |
Why?
|
| Platelet Count | 1 | 2018 | 100 | 0.150 |
Why?
|
| Gastroscopy | 1 | 2018 | 45 | 0.150 |
Why?
|
| Gastric Mucosa | 1 | 2018 | 77 | 0.150 |
Why?
|
| Skin Neoplasms | 1 | 2002 | 375 | 0.150 |
Why?
|
| Survival Analysis | 2 | 2016 | 714 | 0.150 |
Why?
|
| ROC Curve | 2 | 2021 | 392 | 0.140 |
Why?
|
| Serum | 1 | 2016 | 24 | 0.140 |
Why?
|
| Immunoassay | 1 | 2016 | 64 | 0.140 |
Why?
|
| ELAV-Like Protein 1 | 1 | 2016 | 18 | 0.140 |
Why?
|
| World War II | 2 | 2006 | 3 | 0.130 |
Why?
|
| Codes of Ethics | 2 | 2006 | 11 | 0.130 |
Why?
|
| National Socialism | 2 | 2006 | 11 | 0.130 |
Why?
|
| Ethanol | 1 | 2002 | 893 | 0.130 |
Why?
|
| Germany | 2 | 2005 | 67 | 0.130 |
Why?
|
| Child | 3 | 2015 | 6405 | 0.130 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2015 | 34 | 0.130 |
Why?
|
| Medicine in the Arts | 2 | 2006 | 7 | 0.130 |
Why?
|
| Cause of Death | 1 | 2016 | 241 | 0.130 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2017 | 185 | 0.120 |
Why?
|
| Thrombocytopenia | 1 | 2015 | 122 | 0.120 |
Why?
|
| History, Medieval | 2 | 2005 | 8 | 0.120 |
Why?
|
| Laminin | 2 | 2006 | 62 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 2077 | 0.120 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2006 | 74 | 0.120 |
Why?
|
| Patient Selection | 1 | 2018 | 592 | 0.120 |
Why?
|
| Liver Function Tests | 3 | 2015 | 114 | 0.120 |
Why?
|
| Treatment Failure | 2 | 2017 | 216 | 0.110 |
Why?
|
| Proteoglycans | 2 | 2006 | 103 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 307 | 0.110 |
Why?
|
| Critical Care | 1 | 2016 | 263 | 0.110 |
Why?
|
| Drug Combinations | 2 | 2006 | 304 | 0.110 |
Why?
|
| Pilot Projects | 3 | 2015 | 1342 | 0.110 |
Why?
|
| Survival Rate | 1 | 2016 | 1056 | 0.110 |
Why?
|
| Transplant Recipients | 1 | 2014 | 109 | 0.110 |
Why?
|
| Young Adult | 5 | 2021 | 5717 | 0.110 |
Why?
|
| Prevalence | 3 | 2009 | 1619 | 0.100 |
Why?
|
| Hepatectomy | 2 | 2011 | 58 | 0.100 |
Why?
|
| Hypertension, Portal | 2 | 2003 | 53 | 0.100 |
Why?
|
| Survivors | 1 | 2014 | 256 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 756 | 0.100 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2011 | 10 | 0.100 |
Why?
|
| Histocytochemistry | 1 | 2011 | 149 | 0.100 |
Why?
|
| Dilatation, Pathologic | 1 | 2011 | 58 | 0.100 |
Why?
|
| Pain Measurement | 1 | 2012 | 328 | 0.100 |
Why?
|
| Vasodilation | 1 | 2011 | 85 | 0.100 |
Why?
|
| Adenoma, Liver Cell | 1 | 2011 | 1 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 1174 | 0.100 |
Why?
|
| Bile Ducts | 1 | 2011 | 59 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2016 | 447 | 0.100 |
Why?
|
| Child, Preschool | 2 | 2009 | 3187 | 0.100 |
Why?
|
| Collagen | 2 | 2006 | 636 | 0.090 |
Why?
|
| Activities of Daily Living | 1 | 2012 | 319 | 0.090 |
Why?
|
| Antimetabolites | 1 | 2010 | 17 | 0.090 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein D | 1 | 2010 | 6 | 0.090 |
Why?
|
| Sex Factors | 1 | 2014 | 1266 | 0.090 |
Why?
|
| 3' Untranslated Regions | 1 | 2010 | 56 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2012 | 275 | 0.090 |
Why?
|
| Antitubercular Agents | 1 | 2010 | 57 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1040 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1553 | 0.090 |
Why?
|
| RNA Stability | 1 | 2010 | 55 | 0.090 |
Why?
|
| Feasibility Studies | 2 | 2021 | 652 | 0.090 |
Why?
|
| Incidence | 2 | 2012 | 1603 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2010 | 108 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 174 | 0.090 |
Why?
|
| Postoperative Complications | 2 | 2015 | 1615 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2014 | 1330 | 0.080 |
Why?
|
| Age Factors | 1 | 2014 | 1864 | 0.080 |
Why?
|
| Multiple Organ Failure | 1 | 2009 | 36 | 0.080 |
Why?
|
| Cells, Cultured | 2 | 2006 | 2673 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2009 | 164 | 0.080 |
Why?
|
| Anticonvulsants | 1 | 2010 | 223 | 0.080 |
Why?
|
| Disease Progression | 3 | 2021 | 1038 | 0.080 |
Why?
|
| South Carolina | 2 | 2012 | 2752 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2014 | 7029 | 0.080 |
Why?
|
| fas Receptor | 1 | 2007 | 54 | 0.070 |
Why?
|
| Lipotropic Agents | 1 | 2007 | 1 | 0.070 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2007 | 63 | 0.070 |
Why?
|
| Time Factors | 3 | 2017 | 4655 | 0.070 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 201 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2011 | 1174 | 0.070 |
Why?
|
| Protein Binding | 2 | 2010 | 1027 | 0.070 |
Why?
|
| Cell Biology | 1 | 2006 | 4 | 0.070 |
Why?
|
| Morbidity | 1 | 2007 | 130 | 0.070 |
Why?
|
| Global Health | 1 | 2007 | 136 | 0.070 |
Why?
|
| Laparoscopy | 1 | 2008 | 237 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 1536 | 0.070 |
Why?
|
| Antineoplastic Agents | 2 | 2005 | 1070 | 0.070 |
Why?
|
| Hematologic Diseases | 1 | 2006 | 20 | 0.070 |
Why?
|
| Austria | 1 | 2006 | 17 | 0.070 |
Why?
|
| Models, Biological | 1 | 2010 | 981 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2007 | 330 | 0.070 |
Why?
|
| Baseball | 1 | 2005 | 6 | 0.070 |
Why?
|
| Receptors, OSM-LIF | 1 | 2005 | 1 | 0.070 |
Why?
|
| Receptors, Oncostatin M | 1 | 2005 | 1 | 0.070 |
Why?
|
| Keratin-7 | 1 | 2005 | 2 | 0.070 |
Why?
|
| Leukemia Inhibitory Factor Receptor alpha Subunit | 1 | 2005 | 8 | 0.060 |
Why?
|
| Keratins | 1 | 2005 | 48 | 0.060 |
Why?
|
| Biology | 1 | 2005 | 14 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2006 | 127 | 0.060 |
Why?
|
| Environment | 1 | 2006 | 115 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2006 | 140 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2021 | 2007 | 0.060 |
Why?
|
| Protein Subunits | 1 | 2005 | 99 | 0.060 |
Why?
|
| Awards and Prizes | 1 | 2005 | 27 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 196 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 626 | 0.060 |
Why?
|
| Gerbillinae | 1 | 2005 | 156 | 0.060 |
Why?
|
| Antioxidants | 1 | 2007 | 304 | 0.060 |
Why?
|
| Sculpture | 1 | 2004 | 1 | 0.060 |
Why?
|
| Mexico | 1 | 2004 | 38 | 0.060 |
Why?
|
| Species Specificity | 1 | 2005 | 303 | 0.060 |
Why?
|
| Liver Regeneration | 1 | 2004 | 38 | 0.060 |
Why?
|
| Rats, Wistar | 1 | 2005 | 371 | 0.060 |
Why?
|
| Allergy and Immunology | 1 | 2003 | 9 | 0.060 |
Why?
|
| Deficiency Diseases | 1 | 2003 | 1 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2008 | 718 | 0.060 |
Why?
|
| Italy | 1 | 2003 | 36 | 0.060 |
Why?
|
| Art | 1 | 2003 | 2 | 0.060 |
Why?
|
| Egypt | 1 | 2003 | 5 | 0.060 |
Why?
|
| Comorbidity | 1 | 2008 | 1426 | 0.060 |
Why?
|
| Gestational Age | 1 | 2005 | 389 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2005 | 244 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 1026 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 615 | 0.060 |
Why?
|
| Rome | 1 | 2003 | 2 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 514 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2006 | 682 | 0.060 |
Why?
|
| Inclusion Bodies | 1 | 2003 | 10 | 0.050 |
Why?
|
| Poland | 1 | 2003 | 10 | 0.050 |
Why?
|
| Eponyms | 1 | 2003 | 1 | 0.050 |
Why?
|
| Japan | 1 | 2003 | 68 | 0.050 |
Why?
|
| History, 15th Century | 1 | 2002 | 6 | 0.050 |
Why?
|
| Basement Membrane | 1 | 2002 | 48 | 0.050 |
Why?
|
| Plastics | 1 | 2002 | 25 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 786 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2002 | 59 | 0.050 |
Why?
|
| Drama | 1 | 2002 | 6 | 0.050 |
Why?
|
| Medicine in Literature | 1 | 2002 | 5 | 0.050 |
Why?
|
| Spiders | 1 | 2002 | 9 | 0.050 |
Why?
|
| Bilirubin | 1 | 2002 | 51 | 0.050 |
Why?
|
| Esophagoscopy | 1 | 2002 | 72 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2002 | 289 | 0.050 |
Why?
|
| Thrombelastography | 1 | 2021 | 19 | 0.050 |
Why?
|
| Equipment Design | 1 | 2003 | 500 | 0.050 |
Why?
|
| Carbon Isotopes | 1 | 2021 | 54 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2006 | 1034 | 0.050 |
Why?
|
| Actins | 1 | 2002 | 249 | 0.050 |
Why?
|
| Serpins | 1 | 2003 | 205 | 0.050 |
Why?
|
| Heart | 1 | 2005 | 850 | 0.050 |
Why?
|
| Apoptosis | 1 | 2007 | 1641 | 0.050 |
Why?
|
| Infant | 1 | 2007 | 2891 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 546 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 109 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2021 | 411 | 0.040 |
Why?
|
| Biocompatible Materials | 1 | 2002 | 247 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2023 | 332 | 0.040 |
Why?
|
| Hypertension | 1 | 2009 | 1535 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 306 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2002 | 384 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2002 | 1664 | 0.040 |
Why?
|
| Logistic Models | 1 | 2002 | 1420 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2003 | 756 | 0.040 |
Why?
|
| Rats | 1 | 2005 | 5300 | 0.030 |
Why?
|
| Electrochemical Techniques | 1 | 2016 | 23 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2006 | 2689 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 80 | 0.030 |
Why?
|
| Algorithms | 1 | 2002 | 1196 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2016 | 381 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 115 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 3259 | 0.030 |
Why?
|
| Mice | 1 | 2005 | 8474 | 0.030 |
Why?
|
| Aptamers, Nucleotide | 1 | 2010 | 15 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2010 | 35 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2010 | 237 | 0.020 |
Why?
|
| Leukemia | 1 | 2010 | 117 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 322 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2008 | 4848 | 0.020 |
Why?
|
| Hemangioma | 1 | 2008 | 51 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2008 | 79 | 0.020 |
Why?
|
| Cysts | 1 | 2008 | 70 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2008 | 214 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 507 | 0.020 |
Why?
|
| Length of Stay | 1 | 2008 | 780 | 0.020 |
Why?
|
| Probability | 1 | 2005 | 245 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 274 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 320 | 0.010 |
Why?
|
| Registries | 1 | 2005 | 733 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2005 | 2358 | 0.010 |
Why?
|